Nichi-Iko and Sanofi join forces for biosimilar infliximab in Japan
This article was originally published in Scrip
Executive Summary
The large and growing Japanese market for Mitsubishi Tanabe Pharma's (MTP) Remicade (infliximab; licensed from Johnson & Johnson) is continuing to attract biosimilar developers, with Nichi-Iko becoming the latest firm to reveal plans.